Melphalan
- Generic Name
- Melphalan
- Brand Names
- Alkeran, Evomela, Phelinun, Pepaxti
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Cl2N2O2
- CAS Number
- 148-82-3
- Unique Ingredient Identifier
- Q41OR9510P
- Background
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is...
- Indication
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
...
- Associated Conditions
- Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Melphalan in Patients With Neoplastic Meningitis
- Conditions
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2013-02-20
- Lead Sponsor
- Duke University
- Target Recruit Count
- 6
- Registration Number
- NCT00002750
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2010-09-21
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00008229
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma
- Conditions
- First Posted Date
- 2004-05-21
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 750
- Registration Number
- NCT00002599
- Locations
- 🇬🇧
Leeds Teaching Hospital Trust, Leeds, England, United Kingdom
Combination Chemotherapy Followed by Melphalan and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Acute Myeloid Leukemia
- First Posted Date
- 2004-05-20
- Last Posted Date
- 2014-07-28
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 35
- Registration Number
- NCT00004056
- Locations
- 🇺🇸
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Nemours Children's Clinic, Jacksonville, Florida, United States
Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma
- Conditions
- First Posted Date
- 2004-05-12
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 500
- Registration Number
- NCT00002802
- Locations
- 🇩🇪
University of Cologne, Frechen, Germany
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer
- Conditions
- First Posted Date
- 2004-05-03
- Last Posted Date
- 2010-04-02
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 280
- Registration Number
- NCT00003972
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Rituximab in Treating Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2004-04-30
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- The Cleveland Clinic
- Registration Number
- NCT00003554
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2004-04-30
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 25
- Registration Number
- NCT00003397
- Locations
- 🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission
- Conditions
- First Posted Date
- 2004-04-29
- Last Posted Date
- 2010-09-15
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT00002977
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2004-04-29
- Last Posted Date
- 2013-07-24
- Lead Sponsor
- Yale University
- Target Recruit Count
- 40
- Registration Number
- NCT00002680
- Locations
- 🇺🇸
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.